Drugs / Intravenous immune globulin (IVIG)
Intravenous immune globulin (IVIG)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00000935 | ? → Jun 2003 | end stage renal failure | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intravenous immune globulin (IVIG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000935 ↗ |
| Known as | Gamimune-N, 10% | “Patients are randomized to receive IV infusion of either 2 g/kg (maximum dose 180 g) IVIG 10% S/D (Gamimune-N, 10%, manufactured by Bayer) or placebo (0.1% human albumin,...” NCT00000935 ↗ |
| Known as | Intravenous Immune Globulin (Human) | “given at a dose of 20mL/kg Intravenous Immune Globulin (Human) (IVIG 10% solvent/detergent)” NCT00000935 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Intravenous immune globulin (IVIG)” NCT00000935 ↗ |
| Route | Intravenous | “IV infusion” NCT00000935 ↗ |